6141 related articles for article (PubMed ID: 12530072)
1. Augmented growth inhibition of B16-BL6 melanoma by combined treatment with a selective matrix metalloproteinase inhibitor, MMI-166, and cytotoxic agents.
Hojo K; Maki H; Sawada TY; Maekawa R; Yoshioka T
Anticancer Res; 2002; 22(6A):3253-9. PubMed ID: 12530072
[TBL] [Abstract][Full Text] [Related]
2. Augmented anti-metastatic efficacy of a selective matrix metalloproteinase inhibitor, MMI-166, in combination with CPT-11.
Maki H; Hojo K; Tanaka H; Sawada TY; Maekawa R; Yoshioka T
Clin Exp Metastasis; 2002; 19(6):519-26. PubMed ID: 12405289
[TBL] [Abstract][Full Text] [Related]
3. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
4. Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells.
Stamelos VA; Robinson E; Redman CW; Richardson A
Gynecol Oncol; 2013 Feb; 128(2):377-82. PubMed ID: 23168176
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
[TBL] [Abstract][Full Text] [Related]
6. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.
Shalinsky DR; Brekken J; Zou H; Bloom LA; McDermott CD; Zook S; Varki NM; Appelt K
Clin Cancer Res; 1999 Jul; 5(7):1905-17. PubMed ID: 10430098
[TBL] [Abstract][Full Text] [Related]
7. Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma.
Nakajima M; Hayashi K; Egi Y; Katayama K; Amano Y; Uehata M; Ohtsuki M; Fujii A; Oshita K; Kataoka H; Chiba K; Goto N; Kondo T
Cancer Chemother Pharmacol; 2003 Oct; 52(4):319-24. PubMed ID: 12783205
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG
Clin Cancer Res; 2000 Dec; 6(12):4885-92. PubMed ID: 11156248
[TBL] [Abstract][Full Text] [Related]
9. Anti-invasive effect of MMI-166, a new selective matrix metalloproteinase inhibitor, in cervical carcinoma cell lines.
Iwasaki M; Nishikawa A; Fujimoto T; Akutagawa N; Manase K; Endo T; Yoshida K; Maekawa R; Yoshioka T; Kudo R
Gynecol Oncol; 2002 Apr; 85(1):103-7. PubMed ID: 11925127
[TBL] [Abstract][Full Text] [Related]
10. Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model.
O'Reilly T; Lane HA; Wood JM; Schnell C; Littlewood-Evans A; Brueggen J; McSheehy PM
Cancer Chemother Pharmacol; 2011 Jan; 67(1):193-200. PubMed ID: 20512579
[TBL] [Abstract][Full Text] [Related]
11. The effect of monotherapy and combined therapy with NSC-631570 (ukrain) on growth of low- and high-metastasizing B16 melanoma in mice.
Skivka L; Susak Y; Trompak O; Kudryavets Y; Bezdeneznikh N; Semesiuk N; Lykhova O
J Oncol Pharm Pract; 2011 Dec; 17(4):339-49. PubMed ID: 20817651
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Goffin JR; Anderson IC; Supko JG; Eder JP; Shapiro GI; Lynch TJ; Shipp M; Johnson BE; Skarin AT
Clin Cancer Res; 2005 May; 11(9):3417-24. PubMed ID: 15867243
[TBL] [Abstract][Full Text] [Related]
13. Effect of combination therapy with matrix metalloproteinase inhibitor MMI-166 and mitomycin C on the growth and liver metastasis of human colon cancer.
Ohta M; Konno H; Tanaka T; Baba M; Kamiya K; Oba K; Kaneko T; Syouji T; Igarashi A; Nakamura S
Jpn J Cancer Res; 2001 Jun; 92(6):688-95. PubMed ID: 11429059
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of antitumor effects of paclitaxel (taxol) in combination with red ginseng acidic polysaccharide (RGAP).
Shin HJ; Kim YS; Kwak YS; Song YB; Kim YS; Park JD
Planta Med; 2004 Nov; 70(11):1033-8. PubMed ID: 15549658
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor angiogenic effect of a matrix metalloproteinase inhibitor MMI270.
Nakamura ES; Koizumi K; Yamaura T; Saiki I
Anticancer Res; 2003; 23(1A):411-7. PubMed ID: 12680241
[TBL] [Abstract][Full Text] [Related]
16. Dipyridamole augments the antitumor effects of fluorinated pyrimidines.
Sakaguchi Y; Kusumoto T; Kusumoto H; Maehara Y; Furusawa M; Sugimachi K
Anticancer Res; 1992; 12(1):119-21. PubMed ID: 1567156
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
[TBL] [Abstract][Full Text] [Related]
18. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
Donnelly ET; Kelley M; Rockwell S
Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
[TBL] [Abstract][Full Text] [Related]
19. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.
Sirotnak FM; She Y; Lee F; Chen J; Scher HI
Clin Cancer Res; 2002 Dec; 8(12):3870-6. PubMed ID: 12473602
[TBL] [Abstract][Full Text] [Related]
20. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
Garofalo A; Naumova E; Manenti L; Ghilardi C; Ghisleni G; Caniatti M; Colombo T; Cherrington JM; Scanziani E; Nicoletti MI; Giavazzi R
Clin Cancer Res; 2003 Aug; 9(9):3476-85. PubMed ID: 12960140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
